Latest News and Press Releases

GeoJunxion NV (ticker: GOJXN.AS) Financiële en Operationele update 2de kwartaal en 1ste half jaar 2022-23 (juli - december) Belangrijkste punten: 63% omzetgroei voor het 1ste half jaar 2022/23 en...

VANCOUVER, British Columbia, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Standard Lithium Ltd. (“Standard Lithium” or the “Company”) (TSXV: SLI) (NYSE: SLI) (FRA: S5L), a leading pre-commercial lithium...

Belanrijkste punten: 102% omzetgroei voor Q1 2022/23 in vergelijking met dezelfde periode in 2021/22;10% verlaging van de netto operationele kosten (OPEX) voor Q1 2022/23 t.o.v. dezelfde periode in...

Key Facts: 102% revenue growth for Q1 2022/23 compared to the same period in 2021/22;10% reduction in Net Operational Expenses (OPEX) for Q1 2022/23 compared to the same period in 2021/22;EBITDA and...

– CLEAR Outcomes Trial Achieved Last Patient Last Visit in October Ensuring Timely Trial Completion – – Remain On Track to Report Topline Results in January 2023, with Full Results Targeted to be...

ANN ARBOR, Mich., Oct. 17, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report third quarter 2022 financial results before the open of the U.S. financial markets on...

– Achieved 100% of Targeted MACE-4 Accumulation in Unprecedented CLEAR Outcomes Trial; On Track for Topline Results 1Q 2023 – – U.S. Net Product Revenue of NEXLETOL® (bempedoic acid) Tablets and...

Multiple AB-729 and AB-836 HBV clinical data readouts anticipated to guide future clinical development and regulatory strategies Complete IND-enabling studies for oral PD-L1 inhibitor, AB-101, for...

SAN FRANCISCO, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the second quarter ended June 30, 2021. ...

SAN FRANCISCO, July 22, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the second quarter...